OncoMatch/Clinical Trials/NCT05856643
Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Ovarian Epithelial Carcinoma
Is NCT05856643 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies SZ011 CAR-NK for ovarian epithelial carcinoma.
Treatment: SZ011 CAR-NK — This study was a single-center, open-label, investigator-initiated clinical trial (IIT) to observe and investigate the clinical safety and efficacy of SZ011 in the treatment of ovarian epithelial carcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: MSLN positive expression (positive)
Prior therapy
Must have received: first-line treatment
Ovarian cancer patients who have failed or relapsed after first-line treatment
Lab requirements
Blood counts
absolute neutrophil count 1.5109/L; platelets count 50109/L; hemoglobin 80g/L; serum albumin 2.5g/dL
Kidney function
serum creatinine 1.5 times ULN
Liver function
bilirubin 1.5 times ULN; ALT and AST 3 times ULN
absolute neutrophil count 1.5109/L; platelets count 50109/L; hemoglobin 80g/L; serum albumin 2.5g/dL; bilirubin 1.5 times ULN; ALT and AST 3 times ULN; serum creatinine 1.5 times ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify